DOCSLIB.ORG

LYZZ Capital 85

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LYZZ Capital 85 Appendix II Top 100 Longevity Investor Profiles 1. ABN AMRO 34. Flagship Pioneering 67. Partners Innovation Fund 2. Accuitive Medical Ventures 35. Forbion Capital Partners 68. Piper Jaffray Private Capital Group 3. Advantech Capital 36. Formation 8 69. Polaris Partners 4. Alexandria Venture 37. GE Capital 70. RA Capital Management 5. Ally Bridge Group 38. GE Ventures 71. Ramius Advisors 6. ALS Finding a cure 39. General Catalyst 72. Sanofi-Genzyme BioVentures 7. AME Cloud Ventures 40. GV 73. Shibuya Kogyo 8. Amino Capital 41. Harvest Global Investments 74. Silicon Valley Bank 9. Ann Arbor SPARK 42. Horizon Ventures 75. Sino-Alliance International LTD 10. ARCH Venture Partners 43. Illumina 76. S.R.I.W 11. Arkin Holdings 44. Integrale Advisors 77. Sphera Funds Management 12. Aspire Capital Partners LLC 45. Inventages Capital Investment inc 78. Springboard Capital 13. ATEL Ventures 46. Jennison Associates 79. StartUp Health 14. BRCC 47. Juno Therapeutics 80. Sutter Hill Ventures 15. Brainchild Holdings 48. Juvenescence Limited 81. SWMF Life Science Fund 16. Cardinal Partners 49. Khosla Ventures 82. Syno Capital 17. Casdin Capital 50. LabCorp 83. Synthetic Genomics 18. Celgene 51. Legend Capital 84. T. Rowe Price 19. CIRM 52. LYZZ Capital 85. Tan Thay 20. Cyberdyne 53. Magic Stone Alternative 86. Techammer 21. Deep Knowledge Life Sciences 54. Mayo Clinic Ventures 87. Techno Venture Management 22. Deerfield Partners 55. Merck Ventures 88. Testudo Funds 23. DeNovo Ventures 56. NanoDimension 89. The Thiel Foundation 24. DFJ 57. Nazem and Company 90. Third Rock Ventures 25. Easton Capital 58. New Science Ventures 91. Toray Engineering 26. EcoR1 Capital 59. Nivelinvest 92. TVM Capital 27. Eight Roads Ventures 60. Odey Asset Management 93. TYLT Ventures 28. Emerson Collective 61. Odey Swan 94. Venrock 29. Essex Woodlands Health Ventures 62. Omega Funds 95. Versant Ventures 30. F-Prime Capital Partners 63. OrbiMed 96. Vertex Ventures 31. Ferghana Partners 64. OS Fund 97. Viking Global Investors 32. Fidelity Investments 65. Oxford Finance Corporation 98. Vives Fund 33. First Analysis 66. Oxford Sciences Innovation 99. Warburg Pincus 100. WuXi Healthcare Ventures 542 ABN AMRO Summary: ABN AMRO is a Dutch banking company based in Amsterdam. Although they offer financial services, they also offer advice in finance and networking regions. Number of Investments: 40 Headquarters: Amsterdam, Netherlands Year Founded: 1991 Total Investments (USD): $6.95B Stages: Early Stage Venture, Late Stage Venture, Seed Sectors: Fintech Typical Investment: 100k-1M Investments in Geroscience, Regenerative Medicine and P3 Medicine Companies: $15M Series A in April 2015 with 13 other investors (Aaron Levie, AME Cloud Ventures, Drew Houston, Formation 8, Julia Hartz, Katie Stanton, Khosla ventures, Laurene Powell Jobs, Mariam Naficy, Max Levchin, Padmasree Warrior, Raymond Tonsing, Ruchi Sanghvi) 543 Accuitive Medical Ventures Summary: AMV invest in healthcare-related business ventures, specifically targeting device and technology companies at all stages of development. Number of Investments: 45 Headquarters: Duluth, Georgia, USA Year Founded: 2003 Total Investments (USD): N/A Stages: Seed, Early Stage, Late Stage, Debt Financing Sectors: Healthcare, Biotechnology, Medical Devices Typical Investment: $4M - $6M Investments in Geroscience, Regenerative Medicine and P3 Medicine Companies: AxoGen - 12.1M Post-IPO Equity in December 2007 with 3 other investors (Springboard Capital, Cardinal Partners and Denovo Ventures) 544 Advantech Capital Advantech Capital Summary: A Chinese investment firm, Advantech Capital specialises in growth investment and works closely with healthcare companies in China. Number of Investments: 4 Headquarters: China Year Founded: 2015 Total Investments (USD): $215M Stages: Early Stage, Late Stage Sectors: Technology, Healthcare, Media and Communications Typical Investment: $15M-$100M Investments in Geroscience, Regenerative Medicine and P3 Medicine Companies: Harbour BioMed - $50M (Series A) in Dec, 2016 with 1 other investor (Advantech Capital, Legend Capital) 545 Alexandria Venture Summary: Alexandria, a private investment company in San Francisco, provides equity for commercial and residential properties. Their Venture branch forms REIT for Science and Tech companies. Number of Investments: 28 Headquarters: San Francisco, California Year Founded: 1996 Total Investments (USD): $1.3B Stages: Early Stage Sectors: Biotechnology Typical Investment: N/A Investments in Geroscience, Regenerative Medicine and P3 Medicine Companies: Editas Medicine - $120M (Series B) in Aug, 2015 with 14 other investors (Boris Nikolic, Casdin Capital, Deerfield, EcoR1 Capital, Fidelity Management and Research Company, Flagship pioneering, GV, Jennison associates, Khosla Ventures, Omega funds, Polaris partners, T. Rowe Price, Third Rock Ventures, Viking Global Investors) 546 Ally Bridge Group Summary: Ally Bridge is an investment firm specialising in the healthcare technology sector. Number of Investments: 12 Headquarters: Hong Kong, HK Island Year Founded: 2013 Total Investments (USD): $264.07M Stages: Early Stage, Late Stage, Private Equity, Secondary Market, Post IPO Sectors: Biopharmaceuticals, Medical devices Typical Investment: N/A Investments in Geroscience, Regenerative Medicine and P3 Medicine Companies: Hua Medicine - $25M Series B with 1 other investor (Venrock) in January 2015 547 ALS Finding a cure Summary: ALS Finding a cure is a company dedicated to finding solutions and providing support for those suffering from ALS. Consequently, extended funding is placed into research organisations offering support for related diseases and afflictions. Number of Investments: 2 Headquarters: Stamford, Connecticut Year Founded: 2013 Total Investments (USD): $19.96M Stages: Early Stage, Late Stage, Private Equity Sectors: Healthcare Typical Investment: N/A Investments in Geroscience, Regenerative Medicine and P3 Medicine Companies: Emulate Inc. - $17M (Series B) in October 2016 with 2 other investors (ATEL Ventures, Cedars Sinai Medical Center) 548 AME Cloud Ventures Summary: Founded by the original co-founder of 'Yahoo!', AME Cloud Ventures specialises in tech companies that generate vast amounts of interesting data from a multitude of sources. Number of Investments: 152 Headquarters: Palo Alto, California Year Founded: 2012 Total Investments (USD): N/A Stages: Seed, Early Stage, Late Stage Sectors: Cloud Computing, Enterprise Software, Enterprises Typical Investment: N/A Investments in Geroscience, Regenerative Medicine and P3 Medicine Companies: Emulate Inc. - $17M (Series B) in October 2016 with 6 other investors (ATEL Ventures, Cedars Sinai Medical Center, Hansjorg Wyss, NanoDimension, OS Fund, Techammer) 549 Amino Capital Summary: Amino Capital (zPark Capital), based in Palo Alto, is interested in seed to growth-stage investments followed by series A and B investments in data-driven technologies. Number of Investments: 56 Headquarters: Palo Alto, California Year Founded: 2012 Total Investments (USD): $50M Stages: Seed, Early Stage Sectors: Big Data, Health IT, Genomics, Enterprise Software, Consumer Hardware Typical Investment: 200k-10M Investments in Geroscience, Regenerative Medicine and P3 Medicine Companies: Human Longevity Inc.: $220M Series B with 5 other investors (Illumina, Celgene, Draper Fisher Jurvetson, GE Ventures, StartUp Health) in April 2016 550 Ann Arbor SPARK Summary: A non-profit organisation offering programs and pro-active support to businesses. Ann Arbor SPARK works with businesses from different sectors, including engineering, life sciences, and information technologies Number of Investments: 89 Headquarters: Ann Arbor, Michigan Year Founded: 2005 Total Investments (USD): N/A Stages: Seed, Early Stage, Debt Financing Sectors: Healthcare, IT, Social Media, Materials, Alt Energy Typical Investment: $0.05M - $2M Investments in Geroscience, Regenerative Medicine and P3 Medicine Companies: Axonia Medical - $2M Seed in May 2012 with 1 other investor (SWMF Life Sciences Fund) 551 ARCH Venture Partners Summary: Recognised for its success in the commercialisation of technologies developed at research institutes and laboratories, ARCH works with companies to promote innovations in life sciences, physical sciences, and IT. Number of Investments: 238 Headquarters: Chicago, Illinois Year Founded: 1986 Total Investments (USD): $1.2B Stages: Early Stage, Late Stage, Private Equity Sectors: Biotechnology, Healthcare, Clean Technology Typical Investment: $50K - $150M Investments in Geroscience, Regenerative Medicine and P3 Medicine Companies: Bluebird Bio - $60M (Series D) in Jul, 2012 from 6 other Investors (RA Capital Management, Deerfield Partners, Third Rock Ventures, Forbion Capital Partners, TVM Capital, Ramius Advisors); Bluebird Bio - $30M (Venture) in Apr, 2011 from 4 other Investors (Third Rock Ventures, TVM Capital, Forbion Capital Partners, Easton Capital, ARCH Venture Partners) ; Hua Medicine - $50M Series A with 5 other investors (Eight Roads Ventures, F-Prime Capital Partners, Sino-alliance International Ltd., Venrock, WuXi Healthcare Ventures) in September 2011 ; Semma Therapeutics - $44M Series A with 3 other investors (F-Prime Capital Partners, Medtronic, MPM Capital) 552 Arkin Holdings Summary: Arkin Holdings is an Israeli Venture Capital company that does Early Stage Investments. The company focuses on aspiring healthcare R&D enterprises. Number of Investments: 4 Headquarters: Tel Aviv, Israel Year Founded: 2010 Total Investments
Load more

Recommended publications
  • Draper Fisher Jurvetson
    TEAM PORTFOLIO NEWS ABOUT DFJ DFJ NETWORK HOME BACK DRAPER FISHER JURVETSON, DFJ FRONTIER, AND ZONE VENTURES AWARD $250,000 TO NEUROVIGIL IN FOURTH ANNUAL DFJ VENTURE CHALLENGE Draper Fisher Jurvetson, DFJ Frontier, and Zone Ventures Award $250,000 to NeuroVigil in Fourth Annual DFJ Venture Challenge By: Press Release May. 28, 2008 UC San Diego Startup Bests 16 Teams from 12 Universities in Competition for Seed Funding MENLO PARK, Calif ‐‐ Leading early‐stage venture capital firms Draper Fisher Jurvetson (DFJ) and its network partners DFJ Frontier and Zone Ventures hosted the fourth annual DFJ Venture Challenge in Menlo Park on Wednesday. With a grand prize of $250,000 in seed stage funding, the competition is believed to be the largest winner‐take‐all business plan competition for university students. During the morning session, 16 teams from 12 universities on the West Coast presented business plans to a panel of 10 judges, comprised of venture capitalists from the DFJ Network. Six teams were selected as finalists and presented extended versions of their business plans and answered further questions from the judges in a second round of competition in the afternoon. Following the final round of judging, NeuroVigil was awarded $250,000 in seed funding. NeuroVigil is poised to revolutionize brain analysis and plans to target the sleep, transportation, and pharmaceutical industries. The company, which comprises several Nobel Laureates and leading business strategists, was founded in 2007 by Dr. Philip Low, who, as a graduate student at the Salk Institute, developed a new way to analyze brain activity using a single non‐invasive probe.
    [Show full text]
  • Philadelphia Investment Trends Report
    Venture impact Technology investment in the Greater Philadelphia region Trends and highlights, January 2008 to June 2013 Innovation, investment and opportunity On behalf of EY, Ben Franklin Technology Partners of Southeastern Pennsylvania and the Greater Philadelphia Alliance for Capital and Technologies (PACT), we are pleased to present this review 421 companies of technology investment trends and highlights in the Greater Philadelphia region. $4.1 billion The technology investment community in the Greater Philadelphia region includes a wide variety of funding sources supporting a diverse array of companies and industry sectors. In this report, Total investment since we’ve analyzed more than a thousand investment rounds and January 2008 exits that occurred in the Philadelphia region since 2008 – including investments from venture capital fi rms (VCs), angel investors (Angels), corporate/strategic investors, seed funds, accelerators and other sources of funding. As shown in this report, 2012 reversed a post-recession slowdown in venture funding in Greater Philadelphia, and to date, 2013 has brought a welcome increase in the amount of new funds available at regional investment fi rms. These are positive signs for our region’s technology companies, as are the increasing number of exits via IPO and acquisition, which serve as further validation of the investment opportunities created by our region’s growing technology sector. We encourage you to explore this report, and we hope that it will provide useful insights into the current state of
    [Show full text]
  • PREQIN and FIRST REPUBLIC UPDATE: US VENTURE CAPITAL in Q1 2020 PREQIN and FIRST REPUBLIC UPDATE: US VENTURE CAPITAL in Q1 2020 Contents
    PREQIN AND FIRST REPUBLIC UPDATE: US VENTURE CAPITAL IN Q1 2020 PREQIN AND FIRST REPUBLIC UPDATE: US VENTURE CAPITAL IN Q1 2020 Contents 3 Foreword 4 Deals & Exits 7 Fundraising 10 Funds in Market 12 Micro Venture Capital 15 Performance 17 Fund Managers 19 Investors Data Pack The data behind all of the charts featured in this report is available to download for free. Ready-made charts are also included that can be used for presentations, marketing materials, and company reports. Download the data pack Preqin partnered with First Republic Bank to prepare this information regarding US Venture Capital. This report is for information purposes only and is not intended as an offer, solicitation, advice (investment, legal, tax, or otherwise), or as the basis for any contract. First Republic Bank has not independently verified the information contained herein and shall not have liability to any third party in any respect for this report or any actions taken or decisions made based upon anything contained herein. This information is valid only as of April 2020 and neither Preqin nor First Republic Bank will undertake to update this report with regard to changes in market conditions, information, laws, or regulations after the date of this report. This report may not be further reproduced or circulated without the written permission of Preqin and First Republic Bank. All rights reserved. The entire contents of Preqin and First Republic Update: US Venture Capital in Q1 2020 are the Copyright of Preqin Ltd. No part of this publication or any information contained in it may be copied, transmitted by any electronic means, or stored in any electronic or other data storage medium, or printed or published in any document, report or publication, without the express prior written approval of Preqin Ltd.
    [Show full text]
  • RESI Boston Program Guide 09-26-2017 Digital
    SEPTEMBER 26 , 2017 BOSTON, MA Early stage investors, fundraising CEOs, scientist-entrepreneurs, strategic partners, and service providers now have an opportunity to Make a Compelling Connection ONSITE GUIDE LIFE SCIENCE NATION Connecting Products, Services & Capital #RESIBOS17 | RESIConference.com | Boston Marriott Copley Place FLOOR PLAN Therapeutics Track 2 Investor Track 3 & track4 Track 1 Device, Panels Workshops & Diagnostic & HCIT Asia Investor Panels Panels Ad-Hoc Meeting Area Breakfast & Lunch DINING 29 25 30 26 31 27 32 28 33 29 34 30 35 Breakfast / LunchBreakfast BUFFETS 37 28 24 27 23 26 22 25 21 24 20 23 19 22 exhibit hall 40 15 13 16 14 17 15 18 16 19 17 20 18 21 39 INNOVATION 14 12 13 11 12 10 11 9 10 8 9 7 8 EXHIBITORS CHALLENGE 36 38 FINALISTS 1 1 2 2 3 3 4 4 5 5 6 6 7 Partnering Check-in PARTNERING Forum Lunch BUFFETS Breakfast / Breakfast RESTROOM cocktail reception REGISTRATION content Welcome to RESI - - - - - - - - - - - - - - - 2 RESI Agenda - - - - - - - - - - - - - - - - - - 3 BOSTON RESI Innovation Challenge - - - - - - - 5 Exhibiting Companies - - - - - - - - - - 12 Track 1: Therapeutics Investor Panels - - - - - - - - - - - - - - - 19 Track 2: Device, Diagnostic, & HCIT Investor Panels - - - - 29 Track 3: Entrepreneur Workshops - - - - - - - - - - - - - - - - - - 38 Track 4: Asia-North America Workshop & Panels - - - - - - 41 Track 5: Partnering Forum - - - - - - - - - - - - - - - - - - - - - - - - 45 Sponsors & Media Partners - - - - - - - - - - - - - - - - - - - - - - - 46 1 welcome to resi On behalf of Life Science Nation (LSN) and our title sponsors WuXi AppTec and Johnson & Johnson Innovation JLABS, I would like to thank you for joining us at RESI Boston. LSN is very happy to welcome you all to Boston, the city where it all began, for our 14th RESI event.
    [Show full text]
  • Oral History of William H. Draper III
    Oral History of William H. Draper III Interviewed by: John Hollar Recorded: April 14, 2011 Mountain View, California CHM Reference number: X6084.2011 © 2011 Computer History Museum Oral History of William H. Draper III Hollar: So Bill, here I think is the challenge. There's been a great oral history done of you at Berkeley; and then you've written your book. So there's a lot of great information about you on the record. So what I thought we would try to— Draper: That's scary. I hope I say it the same way. Hollar: Well, your version of it is on the record, that's for sure. So I wanted to cover about eight areas in the hour and a half that we have. Draper: Okay. Hollar: Which is quite a bit. But I guess that's also a way of saying—we can go into as much or as little detail as you want to. But the eight areas that I was most interested in covering are your early life and your education; your early career—and with that I mean Inland Steel and meeting Pitch Johnson, and Draper, Gaither & Anderson, that section. Draper: Good. Hollar: Then Draper & Johnson—you and Pitch really getting into it together; then, of course, Sutter Hill and that very incredible fifteen-year period. Draper: Yeah, that was a good period. Hollar: A little bit of what you call "the lost decade." Draper: Okay. Hollar: Then what I call the Draper Richards Renaissance. Draper: Good. Hollar: And kind of the second chapter of venture capital for you.
    [Show full text]
  • Board Meeting Agenda Wednesday, May 26, 2021, 9:30 A.M.* I
    Board Meeting Agenda Wednesday, May 26, 2021, 9:30 a.m.* I. Minutes (Voting Item) II. Executive Director/Chief Investment Officer Report A. PRIT Fund Performance and Markets Update B. Organizational Updates III. PRIM’s Investment Equity Diversity Program Update – “The FUTURE Initiative” IV. Investment Report A. Strategy Group 1. Portfolio Completion Strategies Performance Summary 2. Power Pacific China A-Shares Absolute Return Managed Account (Voting Item) 3. Risk – Benchmarking Review (Voting Item) B. Public Markets 1. Performance Summary 2. Other Credit Opportunities: New Investment Recommendation: Oaktree Fund-of-One (Voting Item) C. Private Equity 1. Performance Summary and Cash Flows 2. Commitment Summary 3. Follow-on Investment Recommendations: (Voting Item) a. Hellman & Friedman Capital Partners Fund X, L.P. b. TA Associates XIV, L.P. and TA Select Opportunities Fund II, L.P. c. Providence Strategic Growth Fund V, L.P. d. Insight Venture Partners XII, L.P., Insight Partners XII Buyout Annex Fund, L.P., and Insight Partners Fund X Follow-On Fund, L.P. e. Quad-C Partners X, L.P. f. Thompson Street Fund VI, L.P. 4. Follow-on Investment Recommendation: Flagship Pioneering Fund VII, L.P. (Voting Item) D. Real Estate and Timberland Performance Summary V. Finance & Administration Report A. Draft Fiscal Year 2022 Operating Budget (Voting Item) B. Issuance of a Request for Proposals (RFP) for Proxy Voting Services (Voting Item) C. Legal/Legislative Update D. Other Matters: 1. March 2021 PRIM Operating Budget 2. Travel Report 3. Client Services *This meeting will be held in accordance with the provisions of the Governor's Order of March 12, 2020 "Suspending Certain Provisions of the Open Meeting Law", and all members of the Board will participate remotely via audio/video conferencing, and public access to the deliberations of the Board will likewise be provided via telephone.
    [Show full text]
  • Howard County Retirement Plans Meeting Materials
    MEETING MATERIALS HOWARD COUNTY RETIREMENT PLANS April 29, 2021 Margaret Belmondo, CIMA®, Partner Will Forde, CFA, CAIA, Principal Francesca LoVerde, Senior Consulting Analyst BOSTON | ATLANTA | CHARLOTTE | CHICAGO | DETROIT | LAS VEGAS | PORTLAND | SAN FRANCISCO TABLE OF CONTENTS Page March Flash Report 3 Correlation & Stochastic Analysis 12 High Yield Search Book 19 2 MARCH FLASH REPORT NEPC, LLC 3 CALENDAR YEAR INDEX PERFORMANCE 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Mar YTD S&P 500 2.1% 16.0% 32.4% 13.7% 1.4% 12.0% 21.8% -4.4% 31.5% 18.4% 4.4% 6.2% Russell 1000 1.5% 16.4% 33.1% 13.2% 0.9% 12.1% 21.7% -4.8% 31.4% 21.0% 3.8% 5.9% Russell 2000 -4.2% 16.3% 38.8% 4.9% -4.4% 21.3% 14.6% -11.0% 25.5% 20.0% 1.0% 12.7% Russell 2500 -2.5% 17.9% 36.8% 7.1% -2.9% 17.6% 16.8% -10.0% 27.8% 20.0% 1.6% 10.9% MSCI EAFE -12.1% 17.3% 22.8% -4.9% -0.8% 1.0% 25.0% -13.8% 22.0% 7.8% 2.3% 3.5% MSCI EM -18.4% 18.2% -2.6% -2.2% -14.9% 11.2% 37.3% -14.6% 18.4% 18.3% -1.5% 2.3% MSCI ACWI -7.3% 16.1% 22.8% 4.2% -2.4% 7.9% 24.0% -9.4% 26.6% 16.3% 2.7% 4.6% Private Equity 9.5% 12.6% 22.3% 14.6% 10.4% 10.3% 21.0% 13.1% 17.2% 13.0%* - - BC TIPS 13.6% 7.0% -8.6% 3.6% -1.4% 4.7% 3.0% -1.3% 8.4% 11.0% -0.2% -1.5% BC Municipal 10.7% 6.8% -2.6% 9.1% 3.3% 0.2% 5.4% 1.3% 7.5% 5.2% 0.6% -0.4% BC Muni High Yield 9.2% 18.1% -5.5% 13.8% 1.8% 3.0% 9.7% 4.8% 10.7% 4.9% 1.1% 2.1% BC US Corporate HY 5.0% 15.8% 7.4% 2.5% -4.5% 17.1% 7.5% -2.1% 14.3% 7.1% 0.1% 0.8% BC US Agg Bond 7.8% 4.2% -2.0% 6.0% 0.5% 2.6% 3.5% 0.0% 8.7% 7.5% -1.2% -3.4% BC Global Agg 5.6% 4.3% -2.6%
    [Show full text]
  • In Eastern Partner Countries
    EU4Digital: supporting digital economy and society in the Eastern Partnership Market Assessment for Digital Innovation and Scale-up Initiative in Eastern partner countries Final report June 2020 1 About this study In early 2020, EU4Digital Facility launched activity ‘Market Assessment for Digital Innovation and Scale-up Initiative (DISC) in Eastern Partner Countries’ (hereinafter – study / research) The goal is to analyse the investment landscape for digital high tech companies in these countries: Armenia, Azerbaijan, Belarus, Georgia, the Republic of Moldova and Ukraine. The activity was inspired by Digital Innovation and Scale-up initiative (DISC) in Central, Eastern and South Eastern Europe region (European Commission Factsheet). Based on the findings of this study, the European Commission will be able to adjust its plans to better serve the needs of the local markets, developing adapted financial support instruments. This research aims to: 1. Understand digital innovation and high-tech start-ups investment landscape and identify existing gaps on investment in Eastern partner countries. 2. Map the main private & corporate equity investors that provide financing to digital start-ups and fast growth companies in Eastern partner countries. 3. Map the main public sector investment programs in start-up / tech-oriented companies at the country-level. 4. Analyse micro-level data on private investments in start-up / tech-oriented companies in the region. 5. Provide recommendations to develop and use financial instruments for digital innovation and the scale-up of high-tech start-ups. The research focuses on start-ups at the creation and scale-up phases, rather than traditional SMEs on their path to digitalisation.
    [Show full text]
  • National Venture Capital Association Venture Capital Oral History Project Funded by Charles W
    National Venture Capital Association Venture Capital Oral History Project Funded by Charles W. Newhall III William H. Draper III Interview Conducted and Edited by Mauree Jane Perry October, 2005 All literary rights in the manuscript, including the right to publish, are reserved to the National Venture Capital Association. No part of the manuscript may be quoted for publication without the written permission of the National Venture Capital Association. Requests for permission to quote for publication should be addressed to the National Venture Capital Association, 1655 North Fort Myer Drive, Suite 850, Arlington, Virginia 22209, or faxed to: 703-524-3940. All requests should include identification of the specific passages to be quoted, anticipated use of the passages, and identification of the user. Copyright © 2009 by the National Venture Capital Association www.nvca.org This collection of interviews, Venture Capital Greats, recognizes the contributions of individuals who have followed in the footsteps of early venture capital pioneers such as Andrew Mellon and Laurance Rockefeller, J. H. Whitney and Georges Doriot, and the mid-century associations of Draper, Gaither & Anderson and Davis & Rock — families and firms who financed advanced technologies and built iconic US companies. Each interviewee was asked to reflect on his formative years, his career path, and the subsequent challenges faced as a venture capitalist. Their stories reveal passion and judgment, risk and rewards, and suggest in a variety of ways what the small venture capital industry has contributed to the American economy. As the venture capital industry prepares for a new market reality in the early years of the 21st century, the National Venture Capital Association reports (2008) that venture capital investments represented 2% of US GDP and was responsible for 10.4 million American jobs and 2.3 trillion in sales.
    [Show full text]
  • Semi-Annual Market Review
    Semi-Annual Market Review HEALTH IT & HEALTH INFORMATION SERVICES JULY 2019 www.hgp.com TABLE OF CONTENTS 1 Health IT Executive Summary 3 2 Health IT Market Trends 6 3 HIT M&A (Including Buyout) 9 4 Health IT Capital Raises (Non-Buyout) 14 5 Healthcare Capital Markets 15 6 Macroeconomics 19 7 Health IT Headlines 21 8 About Healthcare Growth Partners 24 9 HGP Transaction Experience 25 10 Appendix A – M&A Highlights 28 11 Appendix B – Buyout Highlights 31 12 Appendix C – Investment Highlights 34 Copyright© 2019 Healthcare Growth Partners 2 HEALTH IT EXECUTIVE SUMMARY 1 An Accumulating Backlog of Disciplined Sellers Let’s chat about fireside chats. The term first used to describe a series of evening radio addresses given by U.S. President Franklin D. Roosevelt during the Great Depression and World War II is now investment banker speak for “soft launches” of sell-side and capital raise transactions. Every company has a price, and given a market of healthy valuations, more companies are testing the waters to find out whether they can achieve that price. That process now looks a little more informal, or how you might envision a fireside chat. Price (or valuation) discovery for a company can range from a single conversation with an individual buyer to a full-blown auction with hundreds of buyers and everything in between, including a fireside chat. Given the increasing share of informal conversations, the reality is that more companies are for sale than meets the eye. While the healthy valuations publicized and press-released are encouraging more and more companies to price shop, there is a simultaneous statistical phenomenon in perceived valuations that often goes unmentioned: survivorship bias.
    [Show full text]
  • Entrepreneurship in Spain
    All you need to know about entrepreneurship in Spain June 2021 edition A way to make Europe EUROPEAN REGIONAL DEVELOPMENT1 FUND CONTENT Part I – STARTING POINT • Creating a startup Part II – RESOURCES FOR STARTUPS • Resources for startups • Incubators • Accelerators • Specific services suppliers Part III – FINANCING FOR STARTUPS • How to obtain financing • Private sector • Public sector • European calls • National calls Part IV – EVENTS FOR STARTUPS • Events Part V – AUTONOMOUS REGIONS • Programs and subsidies for startups This guide is intended as a collection of resources for startups in their different stages of seeking public and/or private funding 2 Part I Starting point CREATING A STARTUP IN SPAIN The steps to establish a startup are the same as for any other company. The very first one is to determine the most appropriate legal form, a decision that will be influenced by the startup´s later needs regarding participation deals and receipt of third-party investment. The most used legal forms are: Spain • Limited Liability Company (Sociedad Limitada, S.L.) in • Corporation (Sociedad Anónima, S.A.). startup Both forms can also be set up as a sole-shareholder entity (Sociedad Anónima Unipersonal, S.A.U. and Sociedad Limitada Unipersonal, S.L.U. respectively) a at the time of incorporation or be converted into a sole-shareholder entity afterwards. While there are alternatives to these legal forms, they aren´t advisable for startups that will be seeking to add partners to the project and/or third-party investors. For information purposes, these include: Freelancer (Autónomo), Private partnership (Sociedad Civil) or Jointly-Owned Entity (Comunidad de creating Bienes), or a Cooperative (Cooperativa).
    [Show full text]
  • FOGHORN THERAPEUTICS INC. (Name of Issuer)
    SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* FOGHORN THERAPEUTICS INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 344174 10 7 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 27, 2020 (Date of Event Which Requires Filing of Statement on Schedule 13D) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), checking the following box. ☐ * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 344174 10 7 (1) Name of Reporting Persons: Flagship Ventures Fund V, L.P. (2) Check the Appropriate Box if a Member of a Group (See Instructions):
    [Show full text]